Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

risperidone

- PMLiVE

emotive eye healthcare app scoops mobile learning award

The Eye Education app was produced for Johnson & Johnson Vision Care

- PMLiVE

2015’s ‘premium’ prices dissuaded J&J from acquisitions, says Gorsky

More M&A activity anticipated in 2016 and beyond

- PMLiVE

Pharma trio join with top universities for new drug search

AZ, GSK and J&J join forces with Imperial, University College and Cambridge

- PMLiVE

ViiV and Janssen plan pivotal trials of monthly HIV treatment

Rilpivirine – cabotegravir combination could provide a monthly option

- PMLiVE

J&J gets FDA green light for myeloma drug Darzalex

First-in-classtargeted immunotherapy wins US approval

- PMLiVE

FDA approves Alkermes’ long-acting Abilify

Aristada given the nod as injectable antipsychotic

Allergan logo

Allergan and Gedeon finally get antipsychotic green light

Antipsychotic drug Vryalar launches into increasingly competitive market

- PMLiVE

J&J files three-monthly schizophrenia drug in Europe

Hopes to gain advantage over its competitors

- PMLiVE

New iPad app helps schizophrenia patients

Research shows the app ‘Wizard’ could aid memory and independence

- PMLiVE

J&J starts to feel biosimilar competition bite

Secondquarter Remicade sales outside the US dropped 26%

Allergan logo

More waiting for Allergan and Gedeon Richter’s antipsychotic

FDA announced it will take another three months to review cariprazine for schizophrenia

- PMLiVE

FDA approves J&J’s schizophrenia drug Invega Trinza

New version of Invega is the first treatment for the condition to require only four doses a year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links